STEPHEN DAVIS
CIK 1131146 · CEO · last filed 2024-08-20
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$3.96M
Companies
8
Total Filings
109
Lifetime Open-Market Net
-$33.35M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ACAD | CEO | 186,555 | $21.09 | $3.93M | -$33.20M | 40 | 2024-08-20 |
| BELLICUM PHARMACEUTICALS, INC (BLCM) Delisted | Director | 136,854 | $0.07 | $10.2K | $0 | 12 | 2023-01-05 |
| HRTX | Director | 52,032 | $0.40 | $20.8K | $0 | 10 | 2022-12-20 |
| SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | Director | — | — | — | $0 | 5 | 2015-06-23 |
| Furiex Pharmaceuticals, Inc. (FURX) Delisted | Director | 9,308 | — | — | $0 | 2 | 2014-03-04 |
| Ardea Biosciences, Inc./DE (RDEA) Delisted | EVP & COO | 0 | — | — | -$148.9K | 22 | 2012-06-20 |
| HERON THERAPEUTICS, INC. /DE/ (APPA) Delisted | Director | 95,891 | — | — | $0 | 3 | 2011-02-22 |
| NEUROGEN CORP (NRGN) Delisted | President, CEO | — | — | — | $0 | 4 | 2008-07-29 |
Recent Filings · Page 2 of 11
109 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-05-02 | ACAD | Mixed | +7,819 | -$165.3K | EDGAR |
| 2023-04-07 | ACAD | Mixed | +8,751 | -$155.8K | EDGAR |
| 2023-02-27 | ACAD | Mixed | +7,094 | -$72.3K | EDGAR |
| 2023-01-10 | ACAD | Mixed | +5,624 | -$66.9K | EDGAR |
| 2023-01-05 | BELLICUM PHARMACEUTICALS, INC (BLCM) Delisted | Exer (M) | +74,739 | $0 | EDGAR |
| 2022-12-20 | HRTX | Grant (A) | +38,580 | $0 | EDGAR |
| 2022-10-18 | ACAD | Mixed | +3,134 | -$44.3K | EDGAR |
| 2022-09-02 | BELLICUM PHARMACEUTICALS, INC (BLCM) Delisted | Exer (M) | +43,400 | $0 | EDGAR |
| 2022-06-16 | BELLICUM PHARMACEUTICALS, INC (BLCM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-05-03 | ACAD | Mixed | +10,142 | -$99.7K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.